Apollo's mission to extend human health span gets $180M boost, giving VC fund a launchpad for age-related disease biotechs

Apollo Health Ventures has positioned itself to place a fresh round of bets on age-related disease biotechs, raising $180 million to funnel into companies targeting everything from cardiovascular conditions to neurodegenerative diseases.

The transatlantic fund takes a fairly broad view of age-related diseases, casting its net beyond the longevity niche to cover all projects that further its aim of extending human health span. Working out of offices in Boston and Berlin, Apollo is seeking to use its second fund to support the translation of scientific advances in our understanding of how aging drives negative health outcomes.